As the quest to find cancer-specific MCT blockers has been unsuccessful as of yet, others are looking for alternative approaches to blocking lactate shuttling in tumors and cancer, such as by limiting the expression of CD147, the scaffold for MCT insertion into cell membranes (vide supra) (179–182), knocking down lactate dehydrogenase (LDH) expression (183), by preventing the reduction of stromal cell p62 levels (57), or by interfering with lactate signaling by silencing HCAR-1 (9). Here, BSG is linked to cancer.